Blueprint
 
 
FORM 6-K
 
 
SECURITIES AND EXCHANGE COMMISSION

Washington D.C. 20549
 
 
Report of Foreign Issuer
 
 
Pursuant to Rule 13a-16 or 15d-16 of

the Securities Exchange Act of 1934
 
 
 
For period ending 09 February 2017
 
GlaxoSmithKline plc
(Name of registrant)

 
 
 
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address of principal executive offices)

 
 
 
Indicate by check mark whether the registrant files or
will file annual reports under cover Form 20-F or Form 40-F

 
 
 
Form 20-F x     Form 40-F

 
--

 
Indicate by check mark whether the registrant by furnishing the
information contained in this Form is also thereby furnishing the
information to the Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934.

 
 
 
Yes      No x
 
                                                                                                                                                                                                             GlaxoSmithKline plc (the 'Company')
                                                                                                                                                                                                                        Transaction notification
 
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Sir Philip Hampton
b)
Position/status
Non-Executive Chairman
c)
Initial notification/
amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial  instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
   
 
 
b)
Nature of the transaction
Acquisition of notional Ordinary Shares following the annual reinvestment of dividends paid to shareholders throughout 2016 under the share allocation arrangements for Independent Non-Executive Directors.
c)
Price(s) and
volume(s)
Price(s) 
 
Volume(s) 
£15.55
924.285
d)
Aggregated information
 
Aggregated volume Price
n/a (single transaction)
 
 
e)
Date of the transaction
2017-02-08
f)
Place of the transaction
 
n/a
 
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Professor Sir Roy Anderson
b)
Position/status
Independent Non-Executive Director
c)
Initial notification/
amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial  instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
 
 
b)
Nature of the transaction
Acquisition of notional Ordinary Shares following the annual reinvestment of dividends paid to shareholders throughout 2016 under the share allocation arrangements for Independent Non-Executive Directors.
c)
Price(s) and
volume(s)
 Price(s)
 
 Volume(s)
 £15.55
 1,850.161
d)
Aggregated information
 
Aggregated volume Price
n/a (single transaction)
 
 
 
 
 
 
e)
Date of the transaction
2017-02-08
f)
Place of the transaction
 
n/a
 
 
 
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Mr Vindi Banga
b)
Position/status
Senior Independent Non-Executive Director
c)
Initial notification/
amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial  instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
   
 
b)
Nature of the transaction
Acquisition of notional Ordinary Shares following the annual reinvestment of dividends paid to shareholders throughout 2016 under the share allocation arrangements for Independent Non-Executive Directors.
c)
Price(s) and
volume(s)
 Price(s)
 
 Volume(s)
 £15.55
 271.263
d)
Aggregated information
 
Aggregated volume Price
n/a (single transaction)
 
 
 
 
 
 
e)
Date of the transaction
2017-02-08
f)
Place of the transaction
 
n/a
 
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Dr Vivienne Cox
b)
Position/status
Independent Non-Executive Director
c)
Initial notification/
amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial  instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
 
 
 
b)
Nature of the transaction
Acquisition of notional Ordinary Shares following the annual reinvestment of dividends paid to shareholders throughout 2016 under the share allocation arrangements for Independent Non-Executive Directors.
c)
Price(s) and
volume(s)
 Price(s)
 
 Volume(s)
 £15.55
 3.951
d)
Aggregated information
 
Aggregated volume Price
n/a (single transaction)
 
 
 
 
 
 
e)
Date of the transaction
2017-02-08
f)
Place of the transaction
 
n/a
 
 
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Ms Lynn Elsenhans
b)
Position/status
Independent Non-Executive Director
c)
Initial notification/
amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial  instrument
American Depositary Shares ('ADSs')
ISIN: US37733W1053
  
 
 
b)
Nature of the transaction
Acquisition of notional ADSs following the annual reinvestment of dividends paid to shareholders throughout 2016 under the share allocation arrangements for Independent Non-Executive Directors.
c)
Price(s) and
volume(s)
 Price(s)
 
 Volume(s)
 $39.46
 1,177.411
d)
Aggregated information
 
Aggregated volume Price
n/a (single transaction)
 
 
 
 
 
 
e)
Date of the transaction
2017-02-08
f)
Place of the transaction
 
n/a
 
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Ms Judy Lewent
b)
Position/status
Independent Non-Executive Director
c)
Initial notification/
amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial  instrument
American Depositary Shares ('ADSs')
ISIN: US37733W1053 
 
 
b)
Nature of the transaction
Acquisition of notional ADSs following the annual reinvestment of dividends paid to shareholders throughout 2016 under the share allocation arrangements for Independent Non-Executive Directors.
c)
Price(s) and
volume(s)
 Price(s)
 
 Volume(s)
 $39.46
 626.140
d)
Aggregated information
 
Aggregated volume Price
n/a (single transaction)
 
 
 
 
 
 
e)
Date of the transaction
2017-02-08
f)
Place of the transaction
 
n/a
 
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Mr Urs Rohner
b)
Position/status
Independent Non-Executive Director
c)
Initial notification/
amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial  instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882 
 
 
b)
Nature of the transaction
Acquisition of notional Ordinary Shares following the annual reinvestment of dividends paid to shareholders throughout 2016 under the share allocation arrangements for Independent Non-Executive Directors.
c)
Price(s) and
volume(s)
 Price(s)
 
 Volume(s)
 £15.55
 186.803
d)
Aggregated information
 
Aggregated volume Price
n/a (single transaction)
 
 
 
 
 
 
e)
Date of the transaction
2017-02-08
f)
Place of the transaction
 
n/a
 
 
 
 
SIGNATURES
 
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

 
GlaxoSmithKline plc
 
(Registrant)
 
 
Date: February 09, 2017 
 
 
 
 
By: VICTORIA WHYTE
 
 
 
Victoria Whyte
 
Authorised Signatory for and on
 
behalf of GlaxoSmithKline plc